Corcept Therapeutics Incorporated (CORT)

Operating profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Operating income (ttm)	US$ in thousands	107,282	98,112	98,869	100,718	112,634	126,799	131,097	131,608	124,477	118,323	106,810	110,129	128,202	132,708	140,993	130,364	111,609	101,491	91,456	87,457
Revenue (ttm)	US$ in thousands	482,375	450,026	428,153	413,824	401,858	397,624	392,027	380,229	365,978	352,891	343,087	340,064	353,874	356,034	351,212	334,904	306,486	285,422	268,362	258,417
Operating profit margin		22.24%	21.80%	23.09%	24.34%	28.03%	31.89%	33.44%	34.61%	34.01%	33.53%	31.13%	32.38%	36.23%	37.27%	40.14%	38.93%	36.42%	35.56%	34.08%	33.84%

December 31, 2023 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $107,282K ÷ $482,375K
= 22.24%

Corcept Therapeutics Inc has exhibited a declining trend in its operating profit margin over the past eight quarters. The company's operating profit margin decreased from 34.61% in Q1 2022 to 22.24% in Q4 2023. This indicates a reduction in the percentage of revenue that translates into operating profit. While the operating profit margin has fluctuated over the quarters, it is important for the company to closely monitor and manage its operating expenses to improve profitability and operational efficiency.